Device-Less Technique in Islet Transplantation

1. Before any study-specific procedure is performed, valid informed consent will be obtained.
2. A complete medical history will be collected including smoking status and alcohol frequency. On admission to hospital, the recipient will be assessed for fitness to proceed to transplant according to local procedures. If a recipient is deemed unfit for transplant at the time of admission, they will no longer be active on the transplant waiting list and as such will be excluded from the trial.
3. Implantation of the DL sentinel unit: Occurs at Visit 3 (2 Weeks to 24 Weeks Prior to Islet Transplant). One DL sentinel unit will be implanted in the forearm, as deemed appropriate by the Investigator. To conduct the procedure, local anesthesia with sedation may be utilized, with use of general anesthesia at the discretion of the Surgeon. Implantation is executed via incision followed by formation of tissue pockets for each DL unit. Incisions are up to approximately 10 to 30 mm in length, but could vary. The DL unit will consist of a minimum of 5 French (Fr) or up to 7 Fr Torcon NB® Advantage nylon catheters prepared to 8-10 cm in length. Each DL unit will be inserted into one subcutaneous pocket prepared. Surgeons trained on the procedure will have discretion on the ultimate number and length of incisions, but should discuss the details of the implantation plan with the subject prior to the surgery.

• There are inherent surgical risks with the implantation and explantation of DL sentinel units including pain, bleeding, hematoma, seroma, tenderness, redness, scarring, and infection. Steps will be taken to minimize the risks and to make the subject comfortable during the procedure with anesthetic and post-procedure analgesia.
• With any implanted product, the possibility of migration or extrusion of the DL implant exists.
• The use of anesthesia itself may cause side effects. The type(s) of anesthesia used during the implantation and explantation procedures will be determined by the Investigator. Side effects may include, but are not limited to:
• Local Anesthesia: Stinging and/or a burning sensation. Less likely side effects include nausea, vomiting, dizziness, drowsiness, allergic reactions (e.g., redness, itching, and rash), low blood pressure, weakness, severe numbness or tingling, ringing in ears, blurry or double vision, slurred speech, metallic taste in the mouth, mental status change, muscle twitching, and seizures.
• General Anesthesia: Harm to the vocal cords, heart attack, lung infection, and stroke, trauma to the teeth or tongue, or temporary mental confusion. Rarely, waking during anesthesia or death may occur.
• Conscious Sedation: Difficulty breathing.

1. Ultrasound Monitoring Ultrasound monitoring will be performed after DL implantation as per the Principal Investigator's discretion.
2. Standard Islet cell Transplantation: Will occur simultaneously Portal islet transplantation and subcutaneous islet transplantation in the DL sentinel spaces. Standard islet isolation procedures will be followed for all aspects of the islet isolation process. The final islet product will be evaluated based on standard assays used in standard islet isolation practice. Islet transplantation occurs at Visit 4 (Day 0). A minimum target of 4,000 IEQ/kg recipient body weight will be infused either via a percutaneous transhepatic catheter inserted into the portal vein under ultrasound and fluoroscopic guidance, or by open laparotomy under general anesthesia (via cannulation of an omental or mesenteric vein), at the discretion of the investigators. Islets are maintained for a minimum of 6 hours up to 72 hours in supplemented CMRL1066-based media until the time of transplant. The packed islet tissue volume preparation will not exceed 10 cc in order to minimize the risk of portal thrombosis and post-procedural bleeding. Islet transplant into the portal vein is part of Alberta Health Services standard of care procedures. Concomitant to portal vein infusion, islet transplantation will occur in the DL sentinel space. A small incision will be made cranial to the implanted DL unit. A small section of implanted catheter is cut to expose the vascularized tissue scaffold. The DL unit is exposed through the superficial incision and PE-50 or PE-90 tubing containing the human islet preparation is inserted into the lumen of the DL catheter. Approximately 500 - 4000 Islet Equivalent (IEQ), equivalent to 20 μl of islet tissue, will be infused into the DL sentinel. This is based on the original islet mass and packed tissue volume before transplantation and the volume of 8 cm of PE-50 tubing with 0.53 mm inner diameter. The DL catheter is subsequently withdrawn along the PE-50 (or PE-90) tubing and the islets are subsequently infused into the resulting DL lumen.
3. Explantation of DL Sentinels: One quarter of the DL sentinel will be explanted at 2, 4, 12, and 24 weeks post islet transplant, respectively. Experiences in other studies investigating subcutaneous transplantation indicate that while under anesthesia, the units and the surrounding tissue can be explanted with traditional surgical instruments. Local anesthesia is required at a minimum, with the use of sedation or general anesthesia at the discretion of the Surgeon. To explant a unit, the Surgeon will make an incision (re-entry thru the same implant/transplant incision is advocated) and then carefully dissect the tissue engrafted around the transplant. The entire transplant site and any adherent tissue capsule can then be removed entirely from the pocket.

As this is a first in human study, there is the possibility the explantation procedure and technique will be modified based on the data collected.

Participants may receive all required concomitant medications for islet transplant patients: Alemtuzumab, basiliximab, tacrolimus, mycophenolate mofetil, etanercept and anakinra are Standard of Care medications used in the Clinical Islet Transplant program.

Participants in the study receiving their islet transplants will be managed following standard of care including implantation procedure, peri- and post-operative care, post-transplant monitoring, immunosuppression and other medications. For detailed islet transplant standard of care (pre- and post- islet transplant assessments and evaluations), please refer to Appendix B of the study protocol.

1. Portions of the same device-less (DL) biopsy samples will be assessed by histology and MMDx approaches. MMDx assessments of explanted tissue are standardized molecular measurements (probabilities) of transplant rejection or injury.

No additional samples will be required. Samples sent to the (ATAGC) will be coded by the trial personnel. The only required information will be the time of DL explant, post implantation. There will be no additional risks for the patient.